v3.25.2
Segments (Tables)
6 Months Ended
Jun. 30, 2025
Segments [Abstract]  
Schedule of Segment Reporting Reporting by segment is summarized as follows:
Amount in USD  For the six months ended June 30, 2025   For the six months ended June 30, 2024 
   Biotechnology   Pharmaceutical   Total   Biotechnology   Pharmaceutical   Total 
Revenues  $
   $248,536   $248,536   $
   $110,990   $110,990 
Gross margin   
    178,655    178,655    
    95,124    95,124 
Operating expenses:                              
Depreciation and amortization   6,491    
    6,491    9,056    
    9,056 
Selling, general and administrative   484,739    40,281    525,020    363,801    40,574    404,375 
Research and development   144,776    25,553    170,329    124,600    26,449    151,049 
Total Operating expenses   636,006    65,834    701,840    497,457    67,023    564,480 
Other expenses                              
Interest expense   (111,093)   
    (111,093)   (107,487)   
    (107,487)
Fair value adjustment   30,511    
    30,511    (17,996)      (17,996)
Other income (loss), net   1,035    
    1,035    1,707    
    1,707 
Other expenses   (79,547)   
    (79,547)   (123,776)   
    (123,776)
Net income  $(715,553)  $112,821   $(602,732)  $(621,233)  $(28,101)  $(593,132)
                               
Assets of segment  $1,625,478   $341   $1,625,819   $1,375,638   $3,130   $1,378,768 
Schedule of Revenue Revenues for the six months ended June 30, 2025, and 2024 are summarized as follows:
   Six months
ending
   Six months
ending
 
   June 30,
2025
   June 30, 2024 
Service fee for arrangements for sale of Dandruff products  $
-
   $75,147 
Licensing and milestone fees – Luliconazole   116,900    

-

 
Sale of products   121,424    28,113 
Royalty income related to above product sales   10,212    7,730 
Total  $248,536   $110,990